作者
Gabriel Berlingieri Polho, Mateus Trinconi Cunha, Erick Menezes Xavier, Jamile Almeida Silva, Cassio Murilo Trovo Hidalgo Filho, Nathália de Souza Del Rey Crusoé, Marcelo Junqueira Atanazio, Vivian Horita, Guilherme Fialho de Freitas, David Queiroz Borges Muniz, Vanderson Geraldo Rocha, Jose Mauricio Mota
发表日期
2023/2/20
来源
Journal of Clinical Oncology
卷号
41
期号
6_suppl
页码范围
414-414
出版商
American Society of Clinical Oncology
简介
414
Background: HDCT is a potentially curative treatment for pts with aGCT after conventional-dose chemotherapy (CDC). There is scarce evidence of outcomes from aGCT pts treated with HDCT in low and middle-income countries. Methods: We reviewed our institutional database to identify pts with progressive aGCT referred for HDCT following tumor boards. Medical charts were analyzed to extract clinical data. Log-rank was used to compare survival estimates and Cox proportional hazard to determine effects on overall survival (OS). Exploratory correlation and survival trend analysis used synthetic minority oversampling and Spearman’s rho estimated correlations. Results: From 1/2013 to 8/2022, 35 aGCT pts were referred for HDCT. Median age was 28 years (IQR 25-30). Most pts had testicular primary (84%), non-seminoma histology (87%), 1 prior treatment line (62%), poor-risk by IGCCCG (78%), and …
学术搜索中的文章